成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Protein Tyrosine Kinase/RTK
  2. FGFR
  3. LY2874455

LY2874455 是一種 pan-FGFR 抑制劑。LY2874455 抑制 FGFR12,34IC50 分別為 2.8,2.6,6.4 和 6 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

LY2874455 Chemical Structure

LY2874455 Chemical Structure

CAS No. : 1254473-64-7

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥977
In-stock
1 mg ¥454
In-stock
5 mg ¥1000
In-stock
10 mg ¥1538
In-stock
25 mg ¥2825
In-stock
50 mg ¥4500
In-stock
100 mg ¥6000
In-stock
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

LY2874455 is a pan-FGFR inhibitor with IC50s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

IC50 & Target[1]

FGFR1

2.8 nM (IC50)

FGFR2

2.6 nM (IC50)

FGFR3

6.4 nM (IC50)

FGFR4

6 nM (IC50)

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
BaF3 IC50
0.001 μM
Compound: 5; LY2874455
Antiproliferative activity against mouse BAF3 cells expressing wild-type FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
Antiproliferative activity against mouse BAF3 cells expressing wild-type FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
[PMID: 35271262]
BaF3 IC50
340.6 nM
Compound: LY2874455
Antiproliferative activity against mouse BaF3 cells expressing TEL-FGFR4 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antiproliferative activity against mouse BaF3 cells expressing TEL-FGFR4 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
[PMID: 35635004]
Hep 3B2 IC50
0.001 μM
Compound: 5; LY2874455
Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
[PMID: 35271262]
Hep 3B2 IC50
260.8 nM
Compound: LY2874455
Antiproliferative activity against human Hep3B cells expressing FGF19/FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human Hep3B cells expressing FGF19/FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
[PMID: 35635004]
MDA-MB-453 IC50
0.005 μM
Compound: 5; LY2874455
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
[PMID: 35271262]
NCI-H1299 IC50
0.059 μM
Compound: 5; LY2874455
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay
[PMID: 35271262]
NCI-H1581 IC50
< 0.5 nM
Compound: 7
Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay
Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay
[PMID: 27348537]
NCI-H1581 IC50
30.5 nM
Compound: LY2874455
Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
[PMID: 35635004]
RT-112 IC50
8.6 nM
Compound: LY2874455
Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
[PMID: 35635004]
SNU-16 IC50
2.2 nM
Compound: LY2874455
Antiproliferative activity against human SNU-16 cells expressing FGFR2 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Antiproliferative activity against human SNU-16 cells expressing FGFR2 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
[PMID: 35635004]
體外研究
(In Vitro)

LY2874455 在兩種細(xì)胞系中以劑量依賴性方式有效抑制 FGF2 和 FGF9 誘導(dǎo)的 Erk 磷酸化,平均 IC50 值為 0.3 至 0.8 nM。LY2874455 確實(shí)抑制 SNU-16 和 KATO-III 細(xì)胞中的 FGFR2 磷酸化,估計 IC50 值分別為 0.8 和 1.5 nM。此外,LY2874455 抑制 FRS2 的磷酸化,F(xiàn)RS2 是這些細(xì)胞系中 FGFR 的直接下游靶標(biāo),同樣具有 0.8 至 1.5 nM 的相似效力??傊@些結(jié)果表明 LY2874455 抑制細(xì)胞中的 FGFR。LY2874455 對 KMS-11、OPM-2、L-363 和 U266 細(xì)胞的相對 IC50 值分別確定為 0.57、1.0、60.4 和 290.7 nM[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

LY2874455 在所有 4 種測試模型中均表現(xiàn)出快速、穩(wěn)健、劑量依賴性的腫瘤生長抑制作用。重要的是,該分子在 RT-112、SNU-16 和 OPM-2 腫瘤模型中導(dǎo)致腫瘤生長顯著消退,尤其是在每天兩次以 3 mg/kg 劑量給藥時。此外,LY2874455 在 TED50 和 TED90 (1 和 3 mg/kg) 時顯示出優(yōu)秀的藥代動力學(xué)特性。當(dāng)在 RT-112 腫瘤異種移植模型中以間歇給藥方案 (每天兩次,服用 1 周,停藥 1 周或每天兩次,服用 2 天,停藥 2 天) 進(jìn)行測試時,LY2874455 也是有效的。當(dāng)給大鼠服用 1 和 3 mg/kg 的 LY2874455 時,分別是大鼠心臟 IVTI 試驗(yàn)中獲得的 TED50 (0.39 mg/kg) 的 2.6 倍和 7.7 倍,沒有觀察到血壓的顯著變化。然而,當(dāng)給大鼠服用 10 mg/kg 的 LY2874455 (比 TED50 高 25.6 倍) 時,觀察到動脈壓顯著升高[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

444.31

Formula

C21H19Cl2N5O2

CAS 號
性狀

固體

顏色

Off-white to pink

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn): 

DMSO 中的溶解度 : 50 mg/mL (112.53 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響,請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 2.2507 mL 11.2534 mL 22.5068 mL
5 mM 0.4501 mL 2.2507 mL 4.5014 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲存時,請在2年內(nèi)使用, -20°C儲存時,請在1年內(nèi)使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實(shí)驗(yàn):

請根據(jù)您的 實(shí)驗(yàn)動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.63 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (5.63 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液,懸濁液可用于口服和腹腔注射。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
動物溶解方案計算器
請輸入動物實(shí)驗(yàn)的基本信息:

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

由于實(shí)驗(yàn)過程有損耗,建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO ,均可在 MCE 網(wǎng)站選購。 ,Tween 80,均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術(shù)支持聯(lián)系。
動物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上,請謹(jǐn)慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.14%

參考文獻(xiàn)
Kinase Assay
[1]

Reaction mixtures contained 8 mM Tris-HCl (pH 7.5), 10 mM HEPES, 5 mM dithiothreitol, 10 μM ATP, 0.5 μCi 33P-ATP, 10 mM MnCl2, 150 mM NaCl, 0.01% Triton X-100, 4% DMSO, 0.05 mg/mL poly(Glu:Tyr) (4:1, average molecular weight of 20-50 kDa), and 7.5, 7.5, and 16 ng of FGFR1, FGFR3, and FGFR4, respectively, and are incubated at room temperature for 30 minutes followed by termination with 10% H3PO4. The reaction mixtures are transferred to 96-well MAFB filter plates that are washed 3 times with 0.5% H3PO4. After air-drying, the plates are read with a Trilux reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

The different multiple myeloma cancer cell lines KMS-11 and OPM-2 cells, L-363, and U266 cells are used. Cells (2,000 per well) are first grown in RPMI for 6 hours and treated with LY2874455 at 37°C for 3 days. The cells are stained at 37°C for 4 hours and then solubilized at 37°C for 1 hour. Finally, the plate is read at 570 nm using a plate reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
RT-112, OPM-2 (DSMZ), SNU-16, and NCI-H460 cells (RT-112: 2×106 per animal; OPM-2: 107 per animal; SNU-16: 106 per animal; and NCI-H460: 3×106 per animal) are mixed with Matrigel (1:1) and implanted subcutaneously into the rear flank of the mice (female, CD-1 nu/nu for RT-112, OPM-2, and NCI-H460 cells and female, severe combined immunodeficient for SNU-16 cells). The implanted tumor cells grow as solid tumors. To test the efficacy of LY2874455 in these models, the animals are orally dosed with approximately 1 mg/kg (TED50) or 3 mg/kg (TED90) of LY2874455 in 10% Acacia once (every day) or twice a day after tumors reach approximately 150 mm3. The tumor volume and body weight are measured twice a week.
Rats[1]
Four male rats per group are dosed with vehicle (1% hydroxyethylcellulose, 0.25% polysorbate 80, and 0.05% Dow Corning antifoam 1510-US in purified water) on day 1 and LY2874455 (1, 3, and 10 mg/kg) on day 0. On day 1, at least 120 minutes of control data are collected following vehicle administration. On day 0, data are collected for approximately 20 hours beginning after the last animal is dosed.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲存時,請在2年內(nèi)使用, -20°C儲存時,請在1年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2507 mL 11.2534 mL 22.5068 mL 56.2670 mL
5 mM 0.4501 mL 2.2507 mL 4.5014 mL 11.2534 mL
10 mM 0.2251 mL 1.1253 mL 2.2507 mL 5.6267 mL
15 mM 0.1500 mL 0.7502 mL 1.5005 mL 3.7511 mL
20 mM 0.1125 mL 0.5627 mL 1.1253 mL 2.8134 mL
25 mM 0.0900 mL 0.4501 mL 0.9003 mL 2.2507 mL
30 mM 0.0750 mL 0.3751 mL 0.7502 mL 1.8756 mL
40 mM 0.0563 mL 0.2813 mL 0.5627 mL 1.4067 mL
50 mM 0.0450 mL 0.2251 mL 0.4501 mL 1.1253 mL
60 mM 0.0375 mL 0.1876 mL 0.3751 mL 0.9378 mL
80 mM 0.0281 mL 0.1407 mL 0.2813 mL 0.7033 mL
100 mM 0.0225 mL 0.1125 mL 0.2251 mL 0.5627 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機(jī)構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
LY2874455
目錄號:
HY-13304
需求量: